-
Complementary and Alternative Treatments
- Overview of Alternative Treatments - Cancer Tutor
- Personalized Cancer Cocktails
- ITL Alternative Cancer Treament Clinic
- Center for Advancement in Cancer Education
- Hippocrates Health Institute
- BURZYNSKI antineoplaston treatments
- Complementary and alternative cancer treatment: Get the facts
- High pH therapy
- Cesium
Thalidomide
- Mayo Clinic - Thalidomide: Research advances in cancer and other conditions
- Dramatic Responses to Therapy in Rare Tumors: CASE 2. Response in a Patient With Metastatic Adrenal Cortical Carcinoma With Thalidomide
- Personalized Cancer Cocktails - Thalidomide & Avastin
-
Low Dose Naltrexone
- Low Dose Naltrexone General Info
- Gazorpa LDN FAQs
- LDN Yahoo Group
- Additional LDN Yahoo Group
- The long-term survival of a patient with pancreatic cancer with metastases to the liver after treatment with the intravenous alpha-lipoic acid/low-dose naltrexone protocol.
- Methylnaltrexone inhibits opiate and VEGF-induced angiogenesis: role of receptor transactivation.
- Neuroimmunotherapy of untreatable metastatic solid tumors with subcutaneous low-dose interleukin- 2, melatonin and naltrexone: modulation of interleukin- 2-induced antitumor immunity by blocking the opioid system.
-
Tetrathiomolybdate (TM)
- Tetrathiomolybdate - Laboratory Study Explains Clinical Promise Of Anti-Angiogenesis Cancer Drug
- Tetrathiomolybdate (TM) promotes tumour necrosis and suppresses distant metastases in animal model of head and neck cancer
- Cancer therapy with tetrathiomolybdate: antiangiogenesis by lowering body copper--a review.
- Tetrathiomolybdate Inhibits Angiogenesis and Metastasis Through Suppression of the NF{kappa}B Signaling Cascade
-
Stem Cells
- Generic Search
- Scientists Weigh Stem Cells’ Role as Cancer Cause
-
DCA
- The DCA Site
- DCA and Caffeine Warning
- University of Alberta DCA Research Information
- DCA May Cause Liver and Kidney Cancer
- DCA induces apoptosis, decreases proliferation, and inhibits tumor growth, without apparent toxicity.